Prime Updates Toviaz on Medicare Formularies

Prime Therapeutics has removed Toviaz (festoderodine fumarate) from some of its Medicare part D formularies and moved Pfizer’s brand of the overactive bladder therapy to a higher tier in other Medicare formularies.

A generic of Toviaz is now available. The first generic of Tovias from Dr. Reddy’s Laboratories was launched in July 2022. Dr. Reddy’s generic fesoterodine fumarate extended-release tablets are available in 4 mg and 8 mg tablets, each in bottle count sizes of 30.

In Prime’s Ideal, Value Plus, Center of Excellence Formularies, and Client Specific Formularies (Capital Blue Cross), both the 4 mg and 8 mg Tovia will be removed from the list. In the Complete and Expanded Formularies, the branded therapy in both dosage strenghths has been moved to a higher tier.

These changes were effective Aug. 17, 2022.

Toviaz is approved to treat adults with overactive bladder and children six years of age older with neurogenic detrusor overactivity (a bladder dysfunction). In the six months ended June 2022, total worldwide sales of Toviaz were $99 million, a decrease of 16% compared with the first six months of 2021.